Therapy (HCV)

Study Results Suggest Hope for Previously Untreatable Patients

Published in Hepatitis Weekly, November 13th, 2000

Of the nearly four million Americans who suffer from hepatitis C, an estimated one million cannot begin or must discontinue treatment with the current standard of care due to thrombocytopenia (low platelet levels).

Preliminary research presented at the Annual Meeting of the American Association for the Study of Liver Diseases, held in Dallas, Texas, during October 2000, suggests that these patients can begin or continue treatment at full dosage and without interruption when also treated with the platelet growth factor Interleukin-11 (Oprelvekin, marketed under the brand name Neumega).

This first-of-its kind study, conducted at Georgetown University...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry